Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989712 | 0.88 | KMT2A (0.55) | KMT2AMEN1SGMS2RAB9ASMN1; SMN2 | |
| SCHEMBL6107601 | 0.85 | RAB9A (0.60) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6108817 | 0.81 | RAB9A (0.57) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6108434 | 0.79 | RAB9A (0.69) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2986814 | 0.78 | HPD (0.57) | KMT2AMEN1SGMS2ALDH1A1 | |
| SCHEMBL9671326 | 0.77 | HPD (0.54) | KMT2AMEN1SGMS2NPC1HTT | |
| SCHEMBL2438920 | 0.76 | KDM4E (0.73) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL30662860 | 0.75 | KMT2A (0.54) | KMT2AMEN1SGMS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL26604443 | 0.75 | KMT2A (0.54) | KMT2AMEN1SGMS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2991148 | 0.73 | HTT (0.53) | KMT2AMEN1SGMS2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-1336605-B1 | SUBSTITUTED PHENOL DERIVATIVES OR SALTS THEREOF AS INHIBITORS OF COAGULATION FACTOR X | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | EP | disclosed |
| CN-1226292-C | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2005-11-09 | — | — | CN | disclosed |
| EP-1415990-A1 | Diazepan derivatives useful as factor X inhibitor | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040077555-A1 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6642224-B1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1336605-A1 | SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
| CN-1319594-A | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2001-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195193-A1 | Diazepane derivatives or salts thereof | F10, F11, SERPINC1 | KMT2A 364/4885MEN1 449/4885SGMS2 3712/4885 |
| US-20040077555-A1 | Substituted benzene derivatives or salts thereof | F12, F2, HABP2 | KMT2A 3115/4885MEN1 4265/4885SGMS2 3382/4885 |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | F10, SERPINC1, F11 | KMT2A 401/4885MEN1 440/4885SGMS2 3843/4885 |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | PLG, MGAT3, F11 | KMT2A 2322/4885MEN1 3776/4885SGMS2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.